Literature DB >> 32656666

Basal and stimulated calcitonin for the diagnosis of medullary thyroid cancer: updated thresholds and safety assessment.

L Fugazzola1,2, M Di Stefano3,4, S Censi5, A Repaci6, C Colombo3,4, F Grimaldi7, F Magri8, U Pagotto6, M Iacobone9, L Persani3,10, C Mian5.   

Abstract

PURPOSE: Reliable cut-offs for basal (bCT) and calcium stimulated calcitonin (casCT) are needed for an early and accurate diagnosis of medullary thyroid cancer (MTC). PATIENTS AND METHODS: Fifty-four new patients with nodular goiter were enrolled and analysed together with those previously published by our group for a total of 135 cases. bCT and casCT were measured by a highly sensitive method and the results compared with histological findings. In a subgroup of patients, cardiac rhythm was recorded before and during the calcium test.
RESULTS: In both females (F) and males (M), there was a significant correlation between tumor size and bCT levels (P < 0.001). The receiver operating characteristic plot analyses showed that, for bCT, the new cut-off points able to separate non-MTC from MTC patients were > 30 (F) and > 34 pg/mL (M), whereas the best casCT thresholds were > 79 (F) and > 466 pg/mL (M). bCT was shown to harbour a high accuracy, though some cases were diagnosed only upon stimulation test. Importantly, combining bCT, below or above the cut-offs, with casCT above the cut-offs, all the MTC cases were correctly identified. A reversible sinus bradycardia was observed in 9% of cases during the test.
CONCLUSIONS: Refined cut-offs for bCT and casCT in patients with nodular goiter are reported. Sensitive bCT was shown to have a high accuracy, but the combination with casCT data was needed to identify all MTC cases. The reliability and safety of calcium test strongly favour the routine use of CT determination in nodular thyroid disease.

Entities:  

Keywords:  Bradycardia; Calcitonin; Calcium test; Cut-off; Medullary thyroid cancer

Year:  2020        PMID: 32656666      PMCID: PMC7878259          DOI: 10.1007/s40618-020-01356-9

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  21 in total

1.  European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.

Authors:  Furio Pacini; Martin Schlumberger; Henning Dralle; Rossella Elisei; Johannes W A Smit; Wilmar Wiersinga
Journal:  Eur J Endocrinol       Date:  2006-06       Impact factor: 6.664

2.  Histopathological and molecular studies in patients with goiter and hypercalcitoninemia: reactive or neoplastic C-cell hyperplasia?

Authors:  Uberta Verga; Stefano Ferrero; Leonardo Vicentini; Tatiana Brambilla; Valentina Cirello; Marina Muzza; Paolo Beck-Peccoz; Laura Fugazzola
Journal:  Endocr Relat Cancer       Date:  2007-06       Impact factor: 5.678

3.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ASSOCIAZIONE MEDICI ENDOCRINOLOGI MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE DIAGNOSIS AND MANAGEMENT OF THYROID NODULES--2016 UPDATE.

Authors:  Hossein Gharib; Enrico Papini; Jeffrey R Garber; Daniel S Duick; R Mack Harrell; Laszlo Hegedüs; Ralf Paschke; Roberto Valcavi; Paolo Vitti
Journal:  Endocr Pract       Date:  2016-05       Impact factor: 3.443

4.  Italian consensus for the classification and reporting of thyroid cytology.

Authors:  Francesco Nardi; Fulvio Basolo; Anna Crescenzi; Guido Fadda; Andrea Frasoldati; Fabio Orlandi; Lucio Palombini; Enrico Papini; Michele Zini; Alfredo Pontecorvi; Paolo Vitti
Journal:  J Endocrinol Invest       Date:  2014-05-01       Impact factor: 4.256

5.  Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies.

Authors:  F Pacini; F Basolo; R Bellantone; G Boni; M A Cannizzaro; M De Palma; C Durante; R Elisei; G Fadda; A Frasoldati; L Fugazzola; R Guglielmi; C P Lombardi; P Miccoli; E Papini; G Pellegriti; L Pezzullo; A Pontecorvi; M Salvatori; E Seregni; P Vitti
Journal:  J Endocrinol Invest       Date:  2018-05-04       Impact factor: 4.256

6.  Early Diagnosis of Medullary Thyroid Cancer: Are Calcitonin Stimulation Tests Still Indicated in the Era of Highly Sensitive Calcitonin Immunoassays?

Authors:  Martin B Niederle; Christian Scheuba; Philipp Riss; Andreas Selberherr; Oskar Koperek; Bruno Niederle
Journal:  Thyroid       Date:  2020-04-01       Impact factor: 6.568

7.  Influence of chronic autoimmune thyroiditis and papillary thyroid cancer on serum calcitonin levels.

Authors:  Pedro Weslley Rosario; Maria Regina Calsolari
Journal:  Thyroid       Date:  2013-05-28       Impact factor: 6.568

8.  Refining calcium test for the diagnosis of medullary thyroid cancer: cutoffs, procedures, and safety.

Authors:  Caterina Mian; Michela Perrino; Carla Colombo; Elisabetta Cavedon; Gianmaria Pennelli; Stefano Ferrero; Simone De Leo; Cristiano Sarais; Chiara Cacciatore; Gloria Irene Manfredi; Uberta Verga; Maurizio Iacobone; Loredana De Pasquale; Maria Rosa Pelizzo; Leonardo Vicentini; Luca Persani; Laura Fugazzola
Journal:  J Clin Endocrinol Metab       Date:  2014-02-19       Impact factor: 5.958

9.  Calcitonin testing for detection of medullary thyroid cancer in people with thyroid nodules.

Authors:  Hans Hg Verbeek; Jan Willem B de Groot; Wim J Sluiter; Anneke C Muller Kobold; Edwin R van den Heuvel; John Tm Plukker; Thera P Links
Journal:  Cochrane Database Syst Rev       Date:  2020-03-16

10.  Surgical cure rates of sporadic medullary thyroid cancer in the era of calcitonin screening.

Authors:  Andreas Machens; Henning Dralle
Journal:  Eur J Endocrinol       Date:  2016-06-22       Impact factor: 6.664

View more
  6 in total

1.  Safety of calcitonin stimulation tests with calcium.

Authors:  Mara Băetu; Cristina Alexandra Olariu; Ileana Nițu; Gabriel Moldoveanu; Cristina Corneci; Corin Badiu
Journal:  Hormones (Athens)       Date:  2021-09-01       Impact factor: 2.885

Review 2.  Update on the Diagnosis and Management of Medullary Thyroid Cancer: What Has Changed in Recent Years?

Authors:  Krzysztof Kaliszewski; Maksymilian Ludwig; Bartłomiej Ludwig; Agnieszka Mikuła; Maria Greniuk; Jerzy Rudnicki
Journal:  Cancers (Basel)       Date:  2022-07-27       Impact factor: 6.575

3.  Does pretreatment elevated calcitonin level cause the poor prognosis in patients with medullary thyroid cancer?

Authors:  Han Zhang; Daqi Zhang; Chengqiu Sui; Jingting Li; Canxiao Li; Qiao He; Rui Du; Yishen Zhao; Yantao Fu; Le Zhou; Tie Wang; Gianlorenzo Dionigi; Nan Liang; Hui Sun
Journal:  Ann Transl Med       Date:  2022-06

4.  Unilateral Surgery for Medullary Thyroid Carcinoma: Seeking for Clinical Practice Guidelines.

Authors:  Daqi Zhang; Carla Colombo; Hui Sun; Hoon Yub Kim; Antonella Pino; Simone De Leo; Giacomo Gazzano; Luca Persani; Gianlorenzo Dionigi; Laura Fugazzola
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-11       Impact factor: 6.055

5.  Basal and Calcium-Stimulated Procalcitonin for the Diagnosis of Medullary Thyroid Cancers: Lights and Shadows.

Authors:  Simona Censi; Marta Di Stefano; Andrea Repaci; Teresa Benvenuti; Jacopo Manso; Uberto Pagotto; Maurizio Iacobone; Susi Barollo; Loris Bertazza; Francesca Galuppini; Clara Benna; Gianmaria Pennelli; Mario Plebani; Diego Faggian; Carla Colombo; Laura Fugazzola; Caterina Mian
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-13       Impact factor: 5.555

6.  The value of routine measurement of serum calcitonin on insufficient, indeterminate, and suspicious thyroid nodule cytology.

Authors:  Muhammed Erkam Sencar; Sema Hepsen; Murat Çalapkulu; Hayri Bostan; Davut Sakiz; Ilknur Ozturk Unsal; Hakan Duger; Muhammed Kizilgul; Bekir Ucan; Tugba Taskin Turkmenoglu; Mustafa Ozbek; Erman Cakal
Journal:  Bosn J Basic Med Sci       Date:  2022-02-01       Impact factor: 3.363

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.